For the year ending 2025-12-31, TVRD had -$10,880K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -18,214 |
| Depreciation and amortization expense | 95 |
| Stock-based compensation expense | 1,399 |
| Change in fair value of convertible notes | -7,810 |
| Non-cash lease expense | 72 |
| Accretion of net discounts on short-term investments | 200 |
| Interest accrued on convertible notes | 651 |
| Prepaid expenses and other assets | 308 |
| Accounts payable and accrued expenses | 919 |
| Operating lease liabilities | -103 |
| Net cash used in operating activities | -23,499 |
| Purchases of short-term investments | 31,486 |
| Maturities of short-term investments | 21,402 |
| Net cash used in investing activities | -10,084 |
| Cash acquired in connection with the merger | 24,992 |
| Payments for merger transaction costs | 2,821 |
| Proceeds from exercise of stock options | 532 |
| Net cash provided by financing activities | 22,703 |
| Net (decrease) increase in cash and cash equivalents | -10,880 |
| Cash and cash equivalents - beginning of year | 31,614 |
| Cash and cash equivalents - end of year | 20,734 |
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)